- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02248701
Testosterone Plus Finasteride Treatment After Spinal Cord Injury
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Men with spinal cord injury (SCI) experience a high prevalence of hypogonadism which influences the neural, muscular, skeletal, and body composition deficits that occur after injury. It remains unknown whether testosterone administration improves bone mineral density, muscle mass and muscle function, and body composition / metabolic health in hypogonadal men who have experienced ambulatory dysfunction subsequent to incomplete spinal cord injury. In addition, it is unknown whether testosterone or the 5-alpha reduced metabolite dihydrotestosterone (an endogenous metabolite of testosterone) mediate effects in these and other tissues.
For this study hypogonadal men with motor incomplete spinal cord injury who present with ambulatory dysfunction will be randomized to receive testosterone plus the 5-alpha reductase inhibitor finasteride or a placebo treatment for 12 months. Testosterone or placebo injection will be administered weekly; finasteride or placebo will be administered daily. Participants will be assessed at study entry and at 1-6 month intervals thereafter. Assessments will include measurements such as a dual energy x-ray absorptiometry (DEXA) scan, MRI scan, and muscle performance tests. Participants will also have several safety tests, including electrocardiogram (EKG) for cardiac electrophysiology, prostate digital rectal exam and prostate ultrasound sizing for prostate health, and blood tests to assess hematocrit, liver enzymes (AST and ALT), prostate specific antigen (PSA), cholesterol, and other health markers.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- North Florida/South Georgia Veterans Health System, Gainesville, FL
-
Tampa, Florida, United States, 33612
- James A. Haley Veterans' Hospital, Tampa, FL
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male > 18 years of age
- Traumatic, vascular, or orthopedic spinal cord injury between C2-L3 >12 months prior to enrollment
- Motor incomplete spinal cord (AIS C/D)
- Ambulatory dysfunction
- Medically stable condition that is asymptomatic for bladder infection, decubiti, cardiopulmonary disease, or other significant medical conditions
- Serum total testosterone (<325 ng/dL) or bioavailable testosterone (<70 ng/dL)
Exclusion Criteria:
- Currently participating in another research protocol that may influence study outcomes
- Life expectancy <1 year
- History of or current congenital spinal cord injury or other degenerative spinal disorder
- Diagnosis of multiple sclerosis, amyotrophic lateral sclerosis, or other neurologic impairment/injury
- History of venous thromboembolism within the last 6 months, specifically deep venous thromboembolism and pulmonary embolism, history of recurrent venous thromboembolism or know hereditary thrombophilia
- Poorly compensated or uncontrolled cardiovascular disease
- Any major cardiovascular event within the last 12 months (defined as a history of acute myocardial infarction, any cardiac revascularization procedure including angioplasty, stenting, or coronary artery bypass grafting, hospitalization due to unstable angina, transient ischemic attack, or stroke)
- Any angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)
- New York Heart Association (NYHA) class III or IV congestive heart failure
- Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mm Hg
- Poorly controlled arrhythmia
- Severe valvular disease
- LDL cholesterol >160 mg/dl with known history of any major cardiovascular event, as defined above, within the last 12 months
- Baseline EKG findings (e.g. left bundle branch block) or marked EKG abnormalities that would preclude serial screening for occult ischemic events
- Current prostate, breast, or other organ cancer
- History of prostate, breast, or other organ cancer, with the exceptions of completely resolved basal or squamous cell carcinoma for a duration of >24 months or completely resolved melanoma for a duration of >24 months
- Serum prostate-specific antigen (PSA) >3.0 ng/ml
- History of benign prostate enlargement (BPE) >40cc, evaluated via TRUS
- Hematocrit >47%
- Liver enzymes (AST / ALT) above normal upper limit
- Creatinine >1.4 mg/dL
- Serum calcium >10.5 mg/dL
- Gynecomastia
- Mental state that precludes understanding of the protocol
- Diagnosed, but untreated moderate or severe sleep apnea
- Spinal nutrition screening tool score >15
- Severe claustrophobia that precludes MRI testing
- Current anticoagulant therapy
- Use of any of the following pharmacologic agents in the previous 3 months (testosterone, leuprolide, androgenic hormones, growth hormone, oral androgen precursors, 5-alpha reductase or aromatase inhibitors)
- Use of anti-resorptive or bone anabolic drug therapy in the previous 6 months
- Known allergy to sesame oil
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: testosterone enanthate, finasteride
Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
|
Subjects receive testosterone (125 mg/week) by intramuscular injection
Other Names:
Subjects receive finasteride (5 mg/day) orally
Other Names:
|
Placebo Comparator: placebo treatment
Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
|
Subjects receive placebo (weekly) by intramuscular injection
Other Names:
Subjects receive placebo pill (daily) orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Hip Bone Mineral Density
Time Frame: Baseline, 6 months, 12 months
|
Percent change in total hip bone mineral density of the non-dominant limb assessed via dual-energy X-ray absorptiometry (DXA)
|
Baseline, 6 months, 12 months
|
Percent Changes in Muscle Cross-Sectional Area
Time Frame: Baseline, 6 months, 12 months
|
Percent Change in thigh (knee extensors) muscle cross-sectional area of the non-dominant limb assessed via MRI
|
Baseline, 6 months, 12 months
|
Percent Change in Total Body Fat
Time Frame: Baseline, 6 months, 12 months
|
Percent change in total body fat assessed via dual-energy x-ray absorptiometry (DXA)
|
Baseline, 6 months, 12 months
|
Absolute Change in Walking Speed
Time Frame: Baseline, 6 months, 12 months
|
Absolute change in 10 m walking speed
|
Baseline, 6 months, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Neuromuscular Function
Time Frame: Baseline, 6 months, 12 months
|
Percent change in thigh (knee extensors) peak isometric torque production of the non-dominant limb assessed via dynamometry
|
Baseline, 6 months, 12 months
|
Percent Change in Visceral Fat
Time Frame: Baseline, 6 months, 12 months
|
Percent change in visceral (android) fat mass assessed via dual-energy x-ray absorptiometry (DXA)
|
Baseline, 6 months, 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Joshua F Yarrow, PhD MS BS, North Florida/South Georgia Veterans Health System, Gainesville, FL
- Principal Investigator: Dana M Otzel, PhD, North Florida/South Georgia Veterans Health System, Gainesville, FL
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Gait
- Magnetic Resonance Imaging
- Body Composition
- Walking
- Muscle Strength
- Antineoplastic Agents
- Motor Activity
- Pharmacologic Actions
- Locomotion
- Therapeutic Uses
- Testosterone
- Bone Density Conservation Agents
- Muscle Mass
- Androgens
- Hormones
- Bone Formation
- Adipose Tissue
- Bone and Bones
- Antineoplastic Agents, Hormonal
- Bone Mineral Density
- Body Fat
- Testosterone enanthate
- Testosterone undecanoate
- Testosterone 17 beta-cypionate
- Methyltestosterone
- Hormone Substitutes, and Hormone Antagonists
- Physiologic Effects of Drugs
- Anabolic Agents
- Testosterone Replacement Therapy
- Dual Energy X ray Absorptiometry
- Lean Tissue Mass
- Density, Bone
- Bone Resorption
- 5-alpha Reductase
- Lipid and Glucose profile
- Muscle, Skeletal
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Wounds and Injuries
- Nervous System Diseases
- Hypogonadism
- Spinal Cord Diseases
- Spinal Cord Injuries
- Endocrine System Diseases
- Trauma, Nervous System
- Gonadal Disorders
- Central Nervous System Diseases
- Genital Diseases
- Genital Diseases, Male
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Androgens
- 5-alpha Reductase Inhibitors
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
- Finasteride
Other Study ID Numbers
- B1449-R
- 1I01RX001449-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Nervous System Diseases
-
Bracco Diagnostics, IncCompletedCentral Nervous System Neoplasms | Central Nervous System Disease
-
Weill Medical College of Cornell UniversityRecruitingCentral Nervous System Tumor | Pediatric Central Nervous System TumorUnited States
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
Washington University School of MedicineRecruitingCentral Nervous SystemUnited States
-
Washington University School of MedicineLloyd J. Old STAR ProgramTerminatedCentral Nervous System Neoplasms | Central Nervous System TumorUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingCentral Nervous System TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingCentral Nervous System Tumor | Somatic Mutation | Pediatric Central Nervous System Tumor | Discordant TwinUnited States
-
Children's Oncology GroupRecruitingCentral Nervous System CarcinomaUnited States, Puerto Rico
-
Ann & Robert H Lurie Children's Hospital of ChicagoUnknown
Clinical Trials on Testosterone Enanthate
-
Leonard S. Marks, M.D.Watson Pharmaceuticals; Solvay PharmaceuticalsCompletedMen With Low Testosterone LevelsUnited States
-
The University of Texas Medical Branch, GalvestonNational Cancer Institute (NCI)CompletedCachexia | Squamous Cell CarcinomaUnited States
-
University of British ColumbiaVancouver Coastal Health Research InstituteCompleted
-
University of Southern CaliforniaBoston University; University of OregonCompletedOsteoarthritis | Trauma | Muscle Atrophy | ACL ReconstructionUnited States
-
The University of Texas Medical Branch, GalvestonWithdrawn
-
The University of Texas Medical Branch, GalvestonTerminated
-
Antares Pharma Inc.Completed
-
Pennington Biomedical Research CenterUnited States Department of Defense; Defence Research and Development Canada; United States Army Research Institute of Environmental Medicine and other collaboratorsCompletedExercise | Caloric RestrictionUnited States
-
The University of Texas Medical Branch, GalvestonCompleted
-
Eunice Kennedy Shriver National Institute of Child...Unknown